November 2015
 Comme l'année dernière HCS Pharma participe les 1er et 2 décembre prochain au BIOFIT à Strasbourg. Si vous voulez nous rencontrer et en savoir plus sur nos services et nos modèles, c'est une excellente opportunité. Nous serons par exemple très heureux de vous parler de nos récents résultats présentés dans le cadre du congrès ELRIG à Bruxelles. Rendez-vous à Strasbourg !

 Like last year, HCS Pharma will participate in the next BIOFIT event on 1 and 2 December 2015 in Strasbourg. It will be a great opportunity to meet us and discuss about our services and our models. For example, it will be a pleasure to speak with you about our recent results presented in the ELRIGfr conference in Brussels. See you in Strasbourg !
We will be attending BioFIT on 1st and 2nd of December 2015, placed in Strasbourg. BioFIT is one of the best european place to be for B to B meetings since more than 900 companies and 1300 people come to this congress to do business !

Our feedback of lab automation congress of ELRIGfr in Bruxelles

I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results. 
Poster – Genotoxicity assays: assessment of double strand breaks through phospho-H2AX detection and micronuclei analysis in high content screening
Poster – High Content Screening of automated wound healing and cytotoxicity assays in 2D and 3D culture

We win the innovation prize at "Femmes de l'économie Grand Ouest 2015

Our CEO, Nathalie, participated last month at the 2015 edition of the "Femmes de l'économie" contest for the west of France. We are happy to announce that she won the innovation technology prize. We prepare now the national contest, which taking place at the end of november at the french national assembly in Paris.

Φ-score to replace Z score for phenotypic screening

Phenotypic screening by High Content Screening monitors all modification of phenotypic changes. The interest of this technology is having a significant content of biological information (phenotypic and target modifications) and this, cell by cell.

High troughput in HCS in whole organism is the future ?

Complexify cell models to improve relevance of the phenotyic assay in order to find new drugs more efficient is that’s what everyone strives to do. To go further, Zebrafish is a whole organism more and more known and used during the process of drug discovery.

MMP-MT5 a new target for Alzheimer’s disease ?

The Santiago Rivera team of Neurobiology Laboratory of cellular interactions and neurophysiopathology, in collaboration with researchers from the universities of Nice-Sophia Antipolis, Montpellier, Munich and Tokyo, demonstrates for the first time the contribution of the MT5-MMP protease in the development of Alzheimer’s disease in a mouse model.

Standardization of High Content Imaging and Informatics

In this article, authors emphasize the importance of standardisation in the development of HCS. Standards (for Image File Format, Data Integrity and Reference Material) are critical to assure both data quality and reproducibility of assays.


Explain us your requirements and we develop your assays to best meet your needs !

Our vision

To target complex diseases (as cancer and neurodegenerative diseases), more than one target are needed and screening on complex model is recommended.

View this email in your browser
Google Plus
Google Plus
Contact Us
Contact Us
Copyright © 2015 HCS Pharma, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp